EW
EW.US Edwards Lifesciences Corp
- Market cap
- USD 61.6B
- P/E
- 62.3x
- P/B
- 5.60x
- ROE
- 11.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EW.US undervalued?
Graham numberThe Graham number of Edwards Lifesciences Corp cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Edwards Lifesciences Corp fundamental analysis
No fundamental analysis for Edwards Lifesciences Corp yet.
Edwards Lifesciences Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The…
Full company profileEdwards Lifesciences Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Edwards Lifesciences Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.96B | 3.44B | 3.72B | 4.35B | 4.39B | 5.23B | 5.38B | 6.00B | 5.44B | 6.07B | 6.81B |
| Gross Profit | 2.16B | 2.55B | 2.80B | 3.19B | 3.29B | 4.01B | 4.22B | 4.63B | 4.32B | 4.74B | 5.31B |
| Operating Income | 816M | 1.01B | 1.09B | 1.20B | 1.30B | 1.61B | 1.70B | 1.53B | 1.38B | 1.64B | 1.78B |
| EBITDA | 827M | 1.14B | 872M | 1.28B | 1.05B | 1.86B | 1.93B | 1.53B | 1.72B | 1.43B | 1.40B |
| Net Income | 570M | 622M | 722M | 1.05B | 823M | 1.50B | 1.52B | 1.40B | 4.17B | 1.07B | 1.24B |
| EPS | 0.87 | 0.96 | 1.13 | 1.64 | 1.30 | 2.38 | 2.44 | 2.30 | 6.97 | 1.83 | 2.15 |
| Balance Sheet | |||||||||||
| Total Assets | 4.51B | 5.70B | 5.32B | 6.49B | 7.24B | 8.50B | 8.29B | 9.36B | 13.1B | 13.7B | 14.1B |
| Total Liabilities | 1.89B | 2.70B | 2.18B | 2.34B | 2.66B | 2.67B | 2.49B | 2.64B | 2.99B | 3.36B | 3.18B |
| Shareholders' Equity | 2.62B | 2.99B | 3.14B | 4.15B | 4.57B | 5.84B | 5.81B | 6.65B | 10.00B | 10.3B | 10.9B |
| Cash & Short-term Investments | 1.27B | 1.34B | 957M | 1.52B | 1.40B | 1.47B | 1.22B | 1.63B | 3.98B | 4.23B | 4.64B |
| Total Debt | 822M | 1.04B | 594M | 679M | 695M | 690M | 691M | 685M | 700M | 705M | 705M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 704M | 1.00B | 927M | 1.18B | 1.05B | 1.73B | 1.22B | 896M | 542M | 1.60B | 1.69B |
| Capital Expenditure | 217M | 176M | 242M | 278M | 407M | 330M | 265M | 266M | 252M | 260M | 261M |
| Free Cash Flow | 487M | 825M | 685M | 901M | 647M | 1.40B | 953M | 630M | 290M | 1.34B | 1.43B |
| Ratios | |||||||||||
| ROE | 21.7% | 20.8% | 23.0% | 25.2% | 18.0% | 25.8% | 26.2% | 21.1% | 41.8% | 10.4% | 11.4% |
| ROA | 12.6% | 10.9% | 13.6% | 16.1% | 11.4% | 17.7% | 18.4% | 15.0% | 32.0% | 7.8% | 8.8% |
| Net Profit Margin | 19.2% | 18.1% | 19.4% | 24.1% | 18.8% | 28.7% | 28.3% | 23.4% | 76.7% | 17.7% | 18.2% |
| Debt to Equity | 0.31x | 0.35x | 0.19x | 0.16x | 0.15x | 0.12x | 0.12x | 0.10x | 0.07x | 0.07x | 0.06x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Edwards Lifesciences Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 170M | 0.28 | 12.1% |
| 2022 | USD 146M | 0.23 | 9.6% |
| 2021 | USD 159M | 0.25 | 10.6% |
| 2020 | USD 141M | 0.22 | 17.1% |
| 2019 | USD 18.9M | 0.03 | 1.8% |
| 2018 | USD 688M | 1.07 | 95.3% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Jun 1, 2020.
Who owns Edwards Lifesciences Corp
- Insiders 0.20%
- Institutions 94.63%
- Public & others 5.18%
- Shares outstanding 575M
- Free float 573M
Top funds holding EW.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 18.3M | 3.18% | -0.11% | Sep 2026 |
| Vanguard 500 Index Investor | 15.1M | 2.63% | -1.03% | Sep 2026 |
| Vanguard MStar Mid Cap Index Instl | 12.3M | 2.15% | -0.90% | Sep 2026 |
| Vanguard Health Care Inv | 10.5M | 1.83% | -1.60% | Sep 2026 |
| iShares Core S&P 500 ETF | 7.69M | 1.34% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 7.49M | 1.30% | +0.22% | Sep 2026 |
| State Street® SPDR® S&P 500® ETF | 7.04M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 5.49M | 0.96% | -0.18% | Sep 2026 |
| Vanguard MStar Mid Cap Growth ETF | 4.53M | 0.79% | +2.30% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 4.22M | 0.73% | +0.88% | Oct 2026 |
| JPMorgan US Equity L | 3.34M | 0.58% | -7.75% | Sep 2026 |
| Vanguard Windsor II Inv | 3.12M | 0.54% | 0.00% | Sep 2026 |
| BGF World Healthscience A2 | 3.08M | 0.54% | 0.00% | Jul 2026 |
| Vanguard Institutional Index I | 3.05M | 0.53% | -0.99% | Sep 2026 |
| Ninety One GSF Glb Frchs I Acc USD | 2.93M | 0.51% | 0.00% | Jul 2026 |
| UniGlobal | 2.78M | 0.48% | -0.01% | Aug 2026 |
| iShares Russell Mid-Cap ETF | 2.42M | 0.42% | -0.06% | Oct 2026 |
| UniGlobal Vorsorge | 2.41M | 0.42% | -29.32% | Aug 2026 |
| Invesco S&P 500® Equal Weight ETF | 2.29M | 0.40% | +0.17% | Oct 2026 |
| Fidelity Mid Cap Index | 2.19M | 0.38% | +0.88% | Sep 2026 |
Top institutions holding EW.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 58.8M | 10.22% | +11.79% | Jun 2026 |
| Vanguard Capital Management, LLC | 37.6M | 6.54% | -0.30% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 26.4M | 4.59% | +0.02% | Jun 2026 |
| State Street Corp | 26.3M | 4.58% | +0.10% | Jun 2026 |
| JPMorgan Chase & Co | 22.8M | 3.96% | +4.78% | Jun 2026 |
| Wellington Management Company LLP | 16.8M | 2.93% | -23.55% | Jun 2026 |
| Geode Capital Management, LLC | 15.4M | 2.68% | +17.54% | Jun 2026 |
| Bank of New York Mellon Corp | 14.1M | 2.45% | -15.85% | Jun 2026 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 13.0M | 2.26% | +1.49% | Jun 2026 |
| Ninety One UK Limited | 12.3M | 2.15% | -0.47% | Jun 2026 |
| Aristotle Capital Management LLC | 8.67M | 1.51% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 8.66M | 1.51% | +149.77% | Jun 2026 |
| FMR Inc | 8.44M | 1.47% | -41.84% | Jun 2026 |
| NORGES BANK | 8.37M | 1.46% | -11.18% | Jun 2026 |
| Brown Advisory Holdings Inc | 7.37M | 1.28% | +4.79% | Jun 2026 |
| Bank of America Corp | 6.69M | 1.16% | +72.33% | Jun 2026 |
| Artisan Partners Limited Partnership | 6.63M | 1.15% | +27.39% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 6.34M | 1.10% | -10.22% | Jun 2026 |
| Deutsche Bank AG | 5.71M | 0.99% | -5.69% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 5.68M | 0.99% | +200.25% | Jun 2026 |
Edwards Lifesciences Corp company profile
- Company name
- Edwards Lifesciences Corp
- Ticker
- EW.US
- Exchange
- USA Stocks
- Listed since
- Mar 27, 2000
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 16,000
- Fiscal year end
- December
- Address
- One Edwards Way, Irvine, CA, United States, 92614
- Phone
- 949 250 2500
- Website
- edwards.com
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corp management
10- Mr. Bernard J. ZovighianCEO & Director · born 1968
- Mr. Donald E. Bobo Jr.Corporate Vice President of Strategy & Corporate Development · born 1962
- Mr. Daveen ChopraCorporate Vice President of Transcatheter Mitral & Tricuspid Therapies · born 1979
- Ms. Annette Maria BrulsCorporate Vice President of EMEA, Canada, & Latin America · born 1971
- Ms. Theodora MistrasCorporate VP & CFO · born 1982
- Mr. Joseph NuzzoleseCorporate Vice President of Global Operations & Quality
- Mr. Andrew M. DahlPrincipal Accounting Officer, Senior VP & Corporate Controller · born 1978
- Dr. Todd Brinton FACC, M.D.Corporate VP of Advanced Innovation & Technology and Chief Scientific Officer
- Mr. Snehashish SarkarSenior VP and Chief Information & Digital Officer · born 1975
- Mr. Mark D. PetersonCorporate VP & General Counsel · born 1963